Prevalence and Incidence of Heart Failure Among Urban Patients in China: A National Population-Based Analysis,Circulation: Heart Failure

当前位置： X-MOL 学术 › Circ. Heart Fail. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Prevalence and Incidence of Heart Failure Among Urban Patients in China: A National Population-Based Analysis
Circulation: Heart Failure ( IF 9.7 ) Pub Date : 2021-08-28 , DOI: 10.1161/circheartfailure.121.008406
Hua Wang ₁ , Ke Chai ₁ , Minghui Du ₁ , Shengfeng Wang ₂ , Jian-Ping Cai ₃ , Yingying Li ₁ , Ping Zeng ₄ , Wanrong Zhu ₁ , Siyan Zhan _{2,

5} , Jiefu Yang ₁

Affiliation

Background:Large-scale and population-based studies of heart failure (HF) incidence and prevalence are scarce in China. The study sought to estimate the prevalence, incidence, and cost of HF in China.Methods:We conducted a population-based study using records of 50.0 million individuals ≥25 years old from the national urban employee basic medical insurance from 6 provinces in China in 2017. Incident cases were individuals with a diagnosis of HF (International Classification of Diseases code, and text of diagnosis) in 2017 with a 4-year disease-free period (2013–2016). We calculated standardized rates by applying age standardization to the 2010 Chinese census population.Results:The age-standardized prevalence and incidence were 1.10% (1.10% among men and women) and 275 per 100 000 person-years (287 among men and 261 among women), respectively, accounting for 12.1 million patients with HF and 3.0 million patients with incident HF ≥25 years old. Both prevalence and incidence increased with increasing age (0.57%, 3.86%, and 7.55% for prevalence and 158, 892, and 1655 per 100 000 person-years for incidence among persons who were 25–64, 65–79, and ≥80 years of age, respectively). The inpatient mean cost per-capita was $4406.8 and the proportion with ≥3 hospitalizations among those hospitalized was 40.5%. The outpatient mean cost per-capita was $892.3.Conclusions:HF has placed a considerable burden on health systems in China, and strategies aimed at the prevention and treatment of HF are needed.Registration:URL: https://www.clinicaltrials.gov; Unique identifier: ChiCTR2000029094.

更新日期：2021-10-20

点击分享查看原文

点击收藏

阅读更多本刊最新论文

全部期刊列表>>